The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis
Status:
Completed
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
This is a global, multicenter, Phase 2b, randomized, double-blind, placebo-controlled,
two-arm, parallel-group efficacy and safety study of NEOD001 as a single agent administered
intravenously in adults with AL amyloidosis who had a hematologic response to previous
treatment for their amyloidosis (e.g., chemotherapy, autologous stem cell transplant [ASCT])
and have persistent cardiac dysfunction.